Liu Hongwei, Zhou Peng, Ma Peng, Liu Yaqin, Zhang Yingfeng, Li Qiwei, Xu Lingqing, Yuan Wenchang, Yin Weiguo, Li Linhai, Lu Yang
The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Department of Public Health Laboratory Sciences, School of Public Health, Hengyang Medical School, University of South China, Hengyang, China.
Front Microbiol. 2025 May 9;16:1496514. doi: 10.3389/fmicb.2025.1496514. eCollection 2025.
Carbapenem-resistant (CR) Gram-negative pathogens are classified by the WHO as critical threats due to limited therapeutic options. Cefiderocol (CFD), a novel siderophore cephalosporin, shows promise but remains unapproved in China. This study investigated the prevalence, clinical impact, and genetic mechanisms of cefiderocol heteroresistance (CFD-HR) in CR and ESBL-producing clinical isolates from China, where CFD remains unapproved.
A total of 407 CR and ESBL-producing isolates were analyzed. CFD-HR was identified by population analysis profiles (PAPs). Clinical relevance was assessed through disk diffusion susceptibility testing, time-kill assays, and a murine peritonitis model. Genetic mechanisms and stability were elucidated by whole-genome sequencing (WGS) and fitness cost assays.
CFD-HR prevalence was 17.4% (16/92) in carbapenem-resistant (CRAB), 27.9% (24/86) in carbapenem-resistant (CRPA), 23.8% (10/42) in carbapenem-resistant (CRE), and ≤10% (1/10 in ESBL-producing and 8/177 in ESBL-producing ). Although 72.9% (43/59) of HR isolates were classified as CFD-susceptible by disk diffusion, time-kill assays showed that 66.7% (4/6) of HR strains required ≥8 mg/L CFD (vs. 4 mg/L for non-HR) to prevent regrowth. , CFD achieved 100% (3/3) survival in non-HR infections but only 16.7% (4/6) in HR-infected mice. WGS identified transient genetic alterations in HR subpopulations, including duplications (CRE), mutations (CRAB), and SNPs (CRPA), which reverted after antibiotic withdrawal. Fitness cost assays revealed unstable growth deficits in 33.3% (2/6) of HR subpopulations, correlating with genetic instability.
These findings highlight the clinical significance of CFD-HR, even in susceptible isolates, and underscore the need for improved diagnostic methods to detect HR and monitor cross-resistance, offering critical insights for regions transitioning to CFD implementation.
耐碳青霉烯革兰氏阴性病原体被世界卫生组织列为严重威胁,因为治疗选择有限。头孢地尔(CFD)是一种新型铁载体头孢菌素,显示出前景,但在中国仍未获批。本研究调查了中国CFD未获批地区耐碳青霉烯和产超广谱β-内酰胺酶(ESBL)临床分离株中头孢地尔异质性耐药(CFD-HR)的流行情况、临床影响和遗传机制。
共分析了407株耐碳青霉烯和产ESBL的分离株。通过群体分析谱(PAPs)鉴定CFD-HR。通过纸片扩散药敏试验、时间杀菌试验和小鼠腹膜炎模型评估临床相关性。通过全基因组测序(WGS)和适应性代价试验阐明遗传机制和稳定性。
耐碳青霉烯鲍曼不动杆菌(CRAB)中CFD-HR的流行率为17.4%(16/92),耐碳青霉烯铜绿假单胞菌(CRPA)中为27.9%(24/86),耐碳青霉烯肠杆菌科细菌(CRE)中为23.8%(10/42),产ESBL菌株中≤10%(产ESBL菌株中为1/10,产ESBL菌株中为8/177)。尽管72.9%(43/59)的HR分离株通过纸片扩散被分类为对CFD敏感,但时间杀菌试验表明,66.7%(4/6)的HR菌株需要≥8mg/L的CFD(非HR菌株为4mg/L)来防止再生长。在非HR感染中,CFD使存活率达到100%(3/3),但在HR感染的小鼠中仅为16.7%(4/6)。WGS鉴定出HR亚群中的瞬时基因改变,包括重复(CRE)、突变(CRAB)和单核苷酸多态性(CRPA),这些在停用抗生素后恢复。适应性代价试验显示33.3%(2/6)的HR亚群生长存在不稳定缺陷,与基因不稳定性相关。
这些发现突出了CFD-HR的临床意义,即使在敏感分离株中也是如此,并强调需要改进诊断方法以检测HR和监测交叉耐药性,为向CFD实施过渡的地区提供了关键见解。